{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:01:29Z","timestamp":1784228489613,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13181-023-00966-y","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T15:02:11Z","timestamp":1694185331000},"page":"405-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chronic Doxepin Toxicity Masquerading as Epilepsy in a 10-Year-Old Boy"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6927-4427","authenticated-orcid":false,"given":"James D.","family":"Whitledge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. James","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele M.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"issue":"6","key":"966_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S0735-6757(86)80002-X","volume":"4","author":"GE Foulke","year":"1986","unstructured":"Foulke GE, Albertson TE, Walby WF. Tricyclic antidepressant overdose: emergency department findings as predictors of clinical course. Am J Emerg Med. 1986;4(6):496\u2013500.","journal-title":"Am J Emerg Med"},{"issue":"2","key":"966_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/00004714-199004000-00003","volume":"10","author":"SH Preskorn","year":"1990","unstructured":"Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol. 1990;10(2):88\u201395.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"966_CR3","first-page":"160","volume":"53","author":"SH Preskorn","year":"1992","unstructured":"Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry. 1992;53(5):160\u20132.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"966_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","volume":"102","author":"J Hicks","year":"2017","unstructured":"Hicks J, Sangkuhl K, Swen J, Ellingrod V, M\u00fcller D, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37\u201344.","journal-title":"Clin Pharmacol Ther"},{"issue":"03","key":"966_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1055\/s-2003-39983","volume":"36","author":"MJ M\u00fcller","year":"2003","unstructured":"M\u00fcller MJ, Dragicevic A, Fric M, Gaertner I, Grasm\u00e4der K, H\u00e4rtter S, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36(03):98\u2013104.","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"966_CR6","first-page":"23","volume":"52","author":"SH Preskorn","year":"1991","unstructured":"Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry. 1991;52(6):23\u201333.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"966_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3109\/15563650.2012.672987","volume":"50","author":"A Clement","year":"2012","unstructured":"Clement A, Raney JJ, Wasserman GS, Lowry JA. Chronic amitriptyline overdose in a child. Clin Toxicol. 2012;50(5):431\u20134.","journal-title":"Clin Toxicol"},{"issue":"4","key":"966_CR8","first-page":"151","volume":"43","author":"SH Preskorn","year":"1982","unstructured":"Preskorn SH, Irwin HA. Toxicity of tricyclic antidepressants - kinetics, mechanism, intervention: a review. J Clin Psychiatry. 1982;43(4):151\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"1\u20133","key":"966_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.forsciint.2009.05.015","volume":"190","author":"A Gronewold","year":"2009","unstructured":"Gronewold A, Dettling A, Haffner HT, Skopp G. Doxepin and nordoxepin concentrations in body fluids and tissues in doxepin associated deaths. Forensic Sci Int. 2009;190(1\u20133):74\u20139.","journal-title":"Forensic Sci Int"},{"key":"966_CR10","unstructured":"SilenorTM (doxepin) tablets for oral administration [Internet]. US Food and Drug Administration; 2010. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022036lbl.pdf. Accessed 27 May 2023."},{"key":"966_CR11","unstructured":"Doxepin Hydrochloride Capsules, USP Package Insert [Internet]. US Food and Drug Administration; 2014. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/070791s027lbl.pdf. Accessed 27 May 2023."},{"issue":"3","key":"966_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/15563650701226192","volume":"45","author":"AD Woolf","year":"2007","unstructured":"Woolf AD, Erdman AR, Nelson LS, Caravati EM, Cobaugh DJ, Booze LL, et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007;45(3):203\u201333.","journal-title":"Clin Toxicol"},{"key":"966_CR13","unstructured":"ARUP Laboratories [Internet]. 2013. Doxepin and metabolite, serum or plasma. Available from: https:\/\/ltd.aruplab.com\/Tests\/Pub\/0090102. Accessed 31 May 2023."},{"issue":"4","key":"966_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00004714-200108000-00011","volume":"21","author":"S Leucht","year":"2001","unstructured":"Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W. Doxepin plasma concentrations: is there really a therapeutic range? J Clin Psychopharmacol. 2001;21(4):8.","journal-title":"J Clin Psychopharmacol"},{"key":"966_CR15","unstructured":"RPRD Diagnostics [Internet]. Whole pharmacogenomics scan. Available from: https:\/\/www.rprdx.com\/testing\/whole-pharmacogenomics-scan-wps\/alleles\/. Accessed 9 Aug 2023."},{"issue":"5","key":"966_CR16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.5664\/jcsm.8338","volume":"16","author":"YD Shah","year":"2020","unstructured":"Shah YD, Stringel V, Pavkovic I, Kothare SV. Doxepin in children and adolescents with symptoms of insomnia: a single-center experience. J Clin Sleep Med. 2020;16(5):743\u20137.","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"966_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","volume":"151","author":"PK Gillman","year":"2007","unstructured":"Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated: TCAs: pharmacology and interactions. Br J Pharmacol. 2007;151(6):737\u201348.","journal-title":"Br J Pharmacol"},{"key":"966_CR18","unstructured":"Kiskaddon AL. Pediatric obesity presents complexities in medication dosing. Contemp Pediatr. 2022;39(10):31\u20135."},{"issue":"1","key":"966_CR19","first-page":"81","volume":"22","author":"KL Matson","year":"2017","unstructured":"Matson KL, Horton ER, Capino AC. on behalf of the Advocacy Committee for the Pediatric Pharmacy Advocacy Group. Medication Dosage in Overweight and Obese Children. J Pediatr Pharmacol Ther. 2017;22(1):81\u20133.","journal-title":"J Pediatr Pharmacol Ther."},{"key":"966_CR20","unstructured":"Valento M, Liebelt EL. Cyclic Antidepressants. In: Goldfrank\u2019s Toxicologic Emergencies. 11th Edition. New York: McGraw-Hill Education. 2019;1044\u201353."},{"issue":"4","key":"966_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/clpt.2013.254","volume":"95","author":"KR Crews","year":"2014","unstructured":"Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"966_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","volume":"32","author":"M Walzer","year":"2012","unstructured":"Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacother J Hum Pharmacol Drug Ther. 2012;32(4):340\u201353.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"7","key":"966_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1046\/j.1528-1157.2002.41701.x","volume":"43","author":"RC Sachdeo","year":"2002","unstructured":"Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia. 2002;43(7):691\u20136.","journal-title":"Epilepsia"},{"issue":"2","key":"966_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","volume":"49","author":"MJ Hanley","year":"2010","unstructured":"Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71\u201387.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"966_CR25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3949\/ccjm.86a.19005","volume":"86","author":"J Schneider","year":"2019","unstructured":"Schneider J, Patterson M, Jimenez XF. Beyond depression: other uses for tricyclic antidepressants. Cleve Clin J Med. 2019;86(12):807\u201314.","journal-title":"Cleve Clin J Med"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-023-00966-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-023-00966-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-023-00966-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T14:03:36Z","timestamp":1695737016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-023-00966-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1007\/s13181-023-00966-y","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JDW and CJW report no conflicts of interest. MMB is the Pediatric Toxicology Section Editor for UpToDate.Data in this manuscript were previously presented at EAPCCT\u2019s Annual Congress, Mallorca, Spain, 2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}